8-K: Theriva Biologics Reports Positive Phase 2b Trial Results and Secures $7.5 Million in Public Offering

Theriva Biologics announces positive results from its Phase 2b clinical trial of VCN-01 in pancreatic cancer and the closing of a $7.5 million public offering.

Summary

• Theriva Biologics reported its first quarter 2025 financial results and provided a corporate update.
• The VIRAGE Phase 2b clinical trial of VCN-01 with gemcitabine/nab-paclitaxel in metastatic pancreatic cancer met its primary survival and safety endpoints.
• The company closed a public offering on May 8, 2025, raising approximately $7.5 million before expenses.
• General and administrative expenses decreased by 25% to $1.4 million for the quarter ended March 31, 2025.
• Research and development expenses decreased by 14% to $3.0 million for the same period.
• Cash and cash equivalents totaled $10 million as of March 31, 2025, and increased to $14.1 million after the public offering.
• The company intends to use the net proceeds from the offering for working capital, research and development, and manufacturing scale-up of VCN-01.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and a successful capital raise, but also acknowledges ongoing losses and the need for further development. The sentiment is moderately positive.

Positives

• The VIRAGE Phase 2b trial of VCN-01 achieved its primary endpoints, indicating potential therapeutic benefits.
• The public offering provides additional capital to fund research and development and manufacturing scale-up.
• The decrease in general and administrative expenses demonstrates cost management.
• The company is working to scale up manufacturing and finalize the design of a Phase 3 trial of VCN-01.

Negatives

• The company experienced a net loss attributable to common stockholders of $4.324 million, or $1.55 per share, for the three months ended March 31, 2025.
• Cash and cash equivalents decreased from $11.6 million as of December 31, 2024, to $10 million as of March 31, 2025, prior to the public offering.

Risks

• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• The company may face challenges in scaling up manufacturing of VCN-01.
• The company's cash runway is dependent on managing expenses and achieving milestones.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations.

Future Outlook

The company anticipates research and development expenses to increase as it completes the VIRAGE Phase 2b clinical trial, plans for a Phase 3 clinical trial of VCN-01 in PDAC, advances its VCN-01 program in retinoblastoma, expands GMP scale-up manufacturing activities for VCN-01, and continues supporting its other preclinical and discovery initiatives.

Management Comments

• Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, stated that the company has started 2025 with outstanding clinical progress.
• Shallcross highlighted the potential therapeutic benefits of the company's oncolytic virus platform based on the VIRAGE Phase 2b trial results.

Industry Context

The announcement is relevant to the oncology and virotherapy industries, as Theriva Biologics is developing an oncolytic adenovirus platform for cancer treatment. The positive Phase 2b results for VCN-01 in pancreatic cancer could position the company as a potential player in this space.

Comparison to Industry Standards

• The VIRAGE trial's focus on metastatic pancreatic ductal adenocarcinoma aligns with the industry's unmet need for effective treatments for this aggressive cancer.
• Companies like Amgen and Roche are also developing therapies for pancreatic cancer, but Theriva's oncolytic virus approach offers a unique mechanism of action.
• The $7.5 million public offering is relatively small compared to larger biotech companies, but it provides Theriva with necessary capital to advance its clinical programs.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the increased cash balance.
• Employees may benefit from the company's continued growth and development.
• Patients with pancreatic cancer may benefit from the potential approval of VCN-01.
• Suppliers and partners may benefit from the company's increased research and development activities.

Next Steps

• The company is working to scale up manufacturing of VCN-01.
• The company is finalizing the design of a potential Phase 3 confirmatory trial for VCN-01 in mPDAC.
• The company plans to advance its VCN-01 program in retinoblastoma.
• The company will continue supporting its other preclinical and discovery initiatives.

Key Dates

Keywords

VCN-01, pancreatic cancer, clinical trial, Theriva Biologics, SYN-004, public offering, financial results, research and development, oncolytic virus